Dei BioPharma Ltd

What we produce


Trademarked Artavol™, our malaria prevention beverage was developed over the duration of 15 years in state-of-the art universities and laboratories in Africa and the United States.
Artavol comes in two variants, namely powdered mix and juice.

Africa, particularly the tropical regions, houses a superior biodiversity of flora that is the major source of new compounds and molecules that can be discovered to formulate new medicines and drugs.

This is the approach we used to discover the world’s newest antimalarial compounds, as confirmed in labs in the United State, and are expected to replace the current drugs recommended by WHO to treat malaria given the growing resistance of the parasite to these drugs.

According to World Health Organization (WHO), Africa carries a disproportionately high share of the global malaria burden. In 2017, the region was home to 92% (201m) of malaria cases and 93% (404,550) of malaria deaths. The prevalence and mortality from Malaria remains high owing to the fact that mosquitoes bite even before bedtime when people get under a treated mosquito net.

Our primary focus at Dei Biopharma is to discover new drugs and medicines. A vital process since drug resistance is a global challenge and causing deaths to millions in the world.

What we will produce

On top of these, Dei Biopharma Ltd will also manufacture:

  • Inactivated vaccines (used to protect against:- Hepatitis A- Flu (shot only)- Polio (shot only)- Rabies).
    Live-attenuated vaccines (used to protect against:- Measles, mumps, rubella (MMR combined vaccine)- Rotavirus- Smallpox- Chickenpox- Yellow fever).
  • Messenger RNA (mRNA) vaccines (used to protect against:- COVID-19). Subunit, recombinant, polysaccharide, and conjugate vaccines (used to protect against:- Hib (Haemophilus influenzae type b) disease
  • Hepatitis B- HPV (Human papillomavirus)- Whooping cough (part of the DTaP combined vaccine)- Pneumococcal disease- Meningococcal disease- Shingles).
  • Toxoid vaccines (used to protect against DiphtheriaTetanus).
  • Viral vector vaccines (used to protect against:COVID-19).

Types and Capacities

Tablet lines with capacity to produce 30 million tablets per day. Capsule lines with capacity to produce 30 million capsules per day. Fully automated syrup lines with capacity to produce 250 bottles per minute. Ointment lines using the latest technology.

Dei Biopharma has an offtake agreement with the Government of Uganda to manufacture the different types of drugs that the government is currently importing and to hit that target, Dei Biopharma has established the following facilities in the project;

  • The Generics section
  • The Nutraceuticals section
  • The Oncology/cancer drugs
  • Penicillin section
  • The Cephalosporins section
  • Non Beta lactum section
  • The Injectable facilities
  • The WFI facility
  • The Parentals
  • The Ophthalmolic facility

Dei Biopharma Ltd has also set up the iconic YKTM GLP Biotech Laboratories that includes the following components;- Cancer research, QA/QC, drug discovery, Gene therapy, cell therapy, mRNA therapeutics, vaccines, biosimilars and Biologics.

The facility will importantly, have biological facilities to manufacture biological drugs, biosimilars, cytokines, therapeutic protein, peptides and monoclonal antibodies

The above is what makes this facility so unique and is the reason, it will cost us more than $1 billion.

More Services

Dei Group International